Last reviewed · How we verify
TNFR:Fc
TNFR:Fc is a TNF inhibitor Small molecule drug developed by National Eye Institute (NEI). It is currently in Phase 3 development for Rheumatoid arthritis.
TNFR:Fc is a fusion protein that binds to tumor necrosis factor (TNF) and prevents it from interacting with its receptors on cell surfaces.
TNFR:Fc is a fusion protein that binds to tumor necrosis factor (TNF) and prevents it from interacting with its receptors on cell surfaces. Used for Rheumatoid arthritis.
At a glance
| Generic name | TNFR:Fc |
|---|---|
| Sponsor | National Eye Institute (NEI) |
| Drug class | TNF inhibitor |
| Target | TNF |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This prevents the inflammatory response mediated by TNF, which is involved in various autoimmune and inflammatory conditions. By blocking TNF, TNFR:Fc can reduce inflammation and potentially treat conditions such as rheumatoid arthritis.
Approved indications
- Rheumatoid arthritis
Common side effects
- Injection site reaction
- Headache
- Fatigue
- Muscle pain
Key clinical trials
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis (PHASE2, PHASE3)
- Treatment Tapering in JIA With Inactive Disease (PHASE3)
- Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis (PHASE3)
- Psoriasis Longitudinal Assessment and Registry
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (PHASE3)
- TNF-α Treatment of Blast-Induced Tinnitus (PHASE2)
- Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNFR:Fc CI brief — competitive landscape report
- TNFR:Fc updates RSS · CI watch RSS
- National Eye Institute (NEI) portfolio CI
Frequently asked questions about TNFR:Fc
What is TNFR:Fc?
How does TNFR:Fc work?
What is TNFR:Fc used for?
Who makes TNFR:Fc?
What drug class is TNFR:Fc in?
What development phase is TNFR:Fc in?
What are the side effects of TNFR:Fc?
What does TNFR:Fc target?
Related
- Drug class: All TNF inhibitor drugs
- Target: All drugs targeting TNF
- Manufacturer: National Eye Institute (NEI) — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Compare: TNFR:Fc vs similar drugs
- Pricing: TNFR:Fc cost, discount & access